LGVN

Longeveron Inc.

2.27 USD

Last updated Dec 9, 14:52 UTC

Yesterday HIGH

$2.37

Yesterday LOW

$2.25

52w HIGH

$4.58

52w LOW

$1.5

EPS

-0.28

PE

-8.11

Next Earnings

Mar 8, 2024

Overview News Government Trades

Longeveron Inc. stock is up 17.62% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 2 December’s closed higher than November. 100% of analysts rate it a buy.

Longeveron Inc. develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product. It is conducting Phase 1 and 2 clinical trials in various indications.

Stock Exchange

NASDAQ

Sector

Manufacturing

Industry

Pharmaceutical Products

Headquarters

-

Website

longeveron.com

Benzinga Insights

Fri Sep 15, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Newsdesk

Mon Sep 11, 2023

Longeveron Issues Letter To Stockholders; Initiated $30M Rights Offering August 14; Phase 2 ELPIS II Trial In HLHS Surpasses 50% Enrollment

When I joined Longeveron as CEO, I was intrigued by the potential of our lead investigational product Lomecel-B™ in multiple disease states with clear unmet medical needs, and by the scientific foundation laid for
Benzinga Newsdesk

Thu Sep 7, 2023

Long-term Survival Data from Longeveron's ELPIS 1 Trial Accepted for Presentation at the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. (NASDAQ:LGVN, NASDAQ:LGVNR) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions
Benzinga Insights

Wed Sep 6, 2023

Stocks That Hit 52-Week Lows On Wednesday

On Wednesday, 179 companies reached new 52-week lows.
Lisa Levin

Thu Aug 31, 2023

Why Lands' End Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Gainers Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire the company. The transaction will have a total potential value for Acer stockholders of up to $91 million.
Lisa Levin

Thu Aug 31, 2023

US Stocks Rise; Initial Jobless Claims Edge Lower

U.S. stocks traded higher this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded up 0.26% to 34,982.42 while the NASDAQ rose 0.48% to 14,086.54. The S&P 500, also rose, gaining, 0.29% to 4,528.08.
Benzinga Insights

Thu Aug 31, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights

Tue Aug 29, 2023

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 99 stocks hit new 52-week lows.
Happy Mohamed

Mon Aug 14, 2023

Longeveron Announces Pricing For Rights Offering And Expected Calendar; Rights Offering Priced At A $3.00 Subscription Price Per Share

Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as
Happy Mohamed

Fri Aug 11, 2023

Longeveron Announces Achievement Of Surpassing 50% Enrollment Threshold In Phase 2 ELPIS II Study Of Lomecel-BTM In Hypoplastic Left Heart Syndrome

Company Activates Additional Study Location to Expedite Enrollment Completion Key Opinion Leader Webinar Highlighting the Potential for Lomecel-BTM in the Treatment of HLHS to be held Wednesday, August 16,